Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 39 Genitourinary 20 Gynecologic 19 Tumor-Agnostic 13 Other solid neoplasm 11 Gastrointestinal 10 Thoracic 9 Other hematologic neoplasm 7 CNS 4 Sarcoma 3 Myeloid 2 Lymphoid 2 Head & Neck 2 Endocrine 2 Plasma cell 1 NET 1 Classical hematology 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 48 Everolimus 40 Magnetic Resonance Spectroscopy 21 lanreotide 17 Temozolomide 17 gallium Ga 68 dotatate 15 Octreotide 15 pembrolizumab 13 Nivolumab 13 surufatinib 12 Capecitabine 12 cabozantinib 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Sunitinib 10 pasireotide 9 Specimen Handling 9 Positron Emission Tomography Computed Tomography 9 Lutetium-177 9 3-Iodobenzylguanidine 9 Ga(III)-DOTATOC 8 Carboplatin 8 telotristat ethyl 6 copper dotatate CU-64 6 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Ipilimumab 6 Fluorodeoxyglucose F18 6 Etoposide 6 Cisplatin 6 90Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

talazoparib × NET × Clear all

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡